Biosense Technologies Private Limited - Due diligence report

A 360° intelligence report on Biosense: trust score, financial health, credit view, compliance, directors, growth and distress signals - gen…

2008-12-05 Bhiwandi, Maharashtra Active Unlisted Active Compliant
Share
BT Biosense Technologies Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Biosense — 360° Intelligence Report

Generated from MCA filings & public records
78/100
Trust Score
Low Risk

Biosense is assessed as Low Risk with a Trust Score of 78/100. Biosense is an active private limited indian non-government company incorporated in 2008, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Biosense Technologies Private Limited snapshot & full profile →

Financial Health › Neutral
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
78/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
86/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
45/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 55/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Moderate gearing (D/E 38%).

Charges position: 0 open (-) · 2 satisfied (12.00 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Citi Bank N.A.1 48.0 cr
Indian Bank1 48.0 cr
Compliance Score: 86/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 2 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
ALOK KUMAR 01234567 Director 01/04/2018 6 yrs Approved
NARENDRA MAKKAR 01234567 Director 01/04/2018 6 yrs Approved
DEEPAK GURUSHANKAR TRIPATHI 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2022)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Tulip Diagnostics Private Limited
Subsidiaries
-
Group entities
-
Capital events
27 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Tulip Diagnostics Private Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 70 · Distress 75
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Operating for 17+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence80/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment60/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view63/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
29 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
24 Dec 2022
Director ceased
ABHISHEK ABIR SEN
30 Jun 2021
Director ceased
DAISY YIK YAN AUYEUNG
17 Nov 2020
Director ceased
NARENDRANATH SHARATCHANDRA BHAT
23 Sep 2020
Charge satisfied
Citi Bank N.A.
15 Nov 2019
Securities allotted
22950 Equity Shares - 40.07 cr raised
08 Nov 2019
Director ceased
YOGESH VIJAYSING PATIL
07 Nov 2019
Director appointed
ALOK KUMAR (Director)
Director appointed
NARENDRA MAKKAR (Director)
Director appointed
DEEPAK GURUSHANKAR TRIPATHI (Director)
Director ceased
GURMEET KAUR
Director ceased
MUKESH GHANSHYAM SHARMA
04 Nov 2019
Securities allotted
3338 Equity Shares - 33,380.00 raised
09 Oct 2019
Securities allotted
3338 Equity Shares - 33,380.00 raised
10

Key Observations

Auto-generated from the data above
Revenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
All 2 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 27 security allotment(s) - amounts available in the full report.
1 overseas direct investment(s) (ODI) on record - international footprint.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Viral Industries Private Limited U36100GJ2007PTC051414 Ahmedabad, Gujarat, India
Ferrous Crete U24100HR2012PTC045033 Faridabad, Haryana, India
S.B. Zircon Private Limited U51909WB2007PTC117748 Kolkata, West Bengal, India
Harsh Organo-Chem (India) Private Limited U24116GJ2003PTC042761 Gujarat, Gujarat, India
Ruchika Chemical Industries Private Limited U24114MH1997PTC107836 Mumbai, Maharashtra, India
G B Overseas Private Limited U74110DL2007PTC317094 New Delhi, Delhi, India
Chemtexlimited U24100WB2008PLC127895 Kolkata, West Bengal, India
Praveen Laboratories U65910GJ1995PTC026878 Surat, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Biosense before audits and certifications: compliance score 86/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Biosense: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 70/100, margin trends, ownership structure and peer set for Biosense - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 78/100, distress signals and MSME payment-delay disclosures - know whether Biosense pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Biosense - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Biosense an active company?

Biosense has MCA status “Active” with a compliance score of 86/100 (Low Risk).

Is Biosense financially healthy?

Biosense has a Financial Health Score of 45/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Biosense?

Its overall Trust Score is 78/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Biosense?

The ultimate holding entity is Tulip Diagnostics Private Limited. 3 active director(s) are on record.

Does Biosense have loans or charges against its assets?

No open charges - all 2 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Biosense up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 86/100 (Low Risk).

Is it risky to lend to Biosense?

Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.